Proposed Treatment For H1N1 Swine Flu Announced By Energex Systems, Inc.

Main Category: Swine Flu
Also Included In: Flu / Cold / SARS;  Regulatory Affairs / Drug Approvals;  Public Health
Article Date: 30 Apr 2009 - 6:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Healthcare Prof:5 stars

5 (1 votes)


Energex Systems Inc. announced that it has notified the FDA of its interest in applying for an Emergency Use Approval that would permit the company to offer its HemoModulation therapy for the treatment of type A, H1N1, otherwise known as swine flu. HemoModulation therapy was shown to inactivate the virus in mice. This same therapy has been under review by the FDA and is in human clinical trials for Hepatitis C and HIV.

HemoModulation therapy is a process using UVC energy to inactivate the particular strain of virus that the patient is infected with, and returning to the body. The hypothesis is that UV inactivated virus will serve as an autologous vaccine and boost the immune system of the patient against their particular strain of virus. The process takes approximately 30 minutes and can be administered in an office, lab or any other healthcare facility. An animation of the procedure can be viewed at http://www.energexsystems.com/hemomod.htm.

In animal studies, says Thomas Petrie, the company's Director of Research & Development, the therapy produced discernable and substantial improvement in both clinical disease and pulmonary function in mice infected with the H1N1 virus. Minimal clinical illness was observed up to 9 days post infection for those animals that were treated. In contrast, the SHAM-treated animals developed severe illness by day 6 that did not significantly resolve through the 13-day course of the study. As measured by pulmonary lung function testing, infected animals that were treated with HemoModulation therapy exhibited a significantly greater ability to breathe relative to their sham-treated counterparts and pathological examination of lungs clearly indicated that treatment significantly inhibited virus induced inflammation resulting in airways that were for the most part, clear of inflammatory cells and cellular debris. In contrast, the lungs of the sham-treated animals had airways that were filled with inflammatory cells and blood, and exhibited substantial destruction of cells lining the airways.

Source
Energex Systems Inc.

Further information on Swine Flu



Article adapted by Medical News Today from original press release.
Visit our swine flu section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Energex Systems Inc.. "Proposed Treatment For H1N1 Swine Flu Announced By Energex Systems, Inc.." Medical News Today. MediLexicon, Intl., 30 Apr. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/148339.php>

APA
Energex Systems Inc.. (2009, April 30). "Proposed Treatment For H1N1 Swine Flu Announced By Energex Systems, Inc.." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/148339.php.

Please note: If no author information is provided, the source is cited instead.


Swine Flu

Most Popular Articles



Follow Our Swine Flu News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Swine Flu Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »